Dosimetric Comparison of Brain Sparing Between HyperArc and GammaKnife for Single to Triple Brain Metastases.

IF 1.6 4区医学 Q4 ONCOLOGY

Anticancer research Pub Date : 2025-04-01 DOI:10.21873/anticanres.17544

Yoshihiro Ueda, Kanji Mori, Shingo Ohira, Kazuo Tarutani, Naoyuki Kanayama, Ayako Okamura, Koji Konishi

{"title":"Dosimetric Comparison of Brain Sparing Between HyperArc and GammaKnife for Single to Triple Brain Metastases.","authors":"Yoshihiro Ueda, Kanji Mori, Shingo Ohira, Kazuo Tarutani, Naoyuki Kanayama, Ayako Okamura, Koji Konishi","doi":"10.21873/anticanres.17544","DOIUrl":null,"url":null,"abstract":"Background/aim: A novel linac-bases radiosurgery (SRS) system, HyperArc, applied to the non-coplanar volume-modulated arc therapy (VMAT) technique, was developed and released in clinical practice. The aim of the study was to evaluate the dosimetric performance of brain sparing in single-target to three-target cases, for two types of SRS systems: GammaKnife and HyperArc.Patients and methods: A total of 83 patients treated with GammaKnife SRS (35 with single, 24 with double, and 24 with triple metastases) were retrospectively analyzed. Treatment plans were recalculated using HyperArc. Dosimetric parameters, including conformity index (CI), gradient index (GI), and brain volume receiving 2-20 Gy (V2-V20), were compared between the two systems.Results: No significant difference in D99 of the planning target volume (PTV) was observed between GammaKnife and HyperArc. HyperArc exhibited superior CI100, with values approaching 1.0. V4-V20 for the whole brain minus PTV were significantly lower for HyperArc than GammaKnife. In single-target cases, GI was significantly lower for HyperArc, while in triple-target cases, it was higher. V12 volumes for HyperArc were comparable to those for GammaKnife, even in cases with volumes <1.0 cm3.Conclusion: HyperArc demonstrated dosimetric performance comparable to or better than GammaKnife in brain sparing for single-to-triple metastases. These findings support HyperArc as an effective alternative for SRS planning.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 4","pages":"1631-1641"},"PeriodicalIF":1.6000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17544","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: A novel linac-bases radiosurgery (SRS) system, HyperArc, applied to the non-coplanar volume-modulated arc therapy (VMAT) technique, was developed and released in clinical practice. The aim of the study was to evaluate the dosimetric performance of brain sparing in single-target to three-target cases, for two types of SRS systems: GammaKnife and HyperArc.

Patients and methods: A total of 83 patients treated with GammaKnife SRS (35 with single, 24 with double, and 24 with triple metastases) were retrospectively analyzed. Treatment plans were recalculated using HyperArc. Dosimetric parameters, including conformity index (CI), gradient index (GI), and brain volume receiving 2-20 Gy (V₂-V₂₀), were compared between the two systems.

Results: No significant difference in D₉₉ of the planning target volume (PTV) was observed between GammaKnife and HyperArc. HyperArc exhibited superior CI₁₀₀, with values approaching 1.0. V₄-V₂₀ for the whole brain minus PTV were significantly lower for HyperArc than GammaKnife. In single-target cases, GI was significantly lower for HyperArc, while in triple-target cases, it was higher. V₁₂ volumes for HyperArc were comparable to those for GammaKnife, even in cases with volumes <1.0 cm³.

Conclusion: HyperArc demonstrated dosimetric performance comparable to or better than GammaKnife in brain sparing for single-to-triple metastases. These findings support HyperArc as an effective alternative for SRS planning.

查看原文本刊更多论文

HyperArc和GammaKnife治疗单次至三次脑转移的脑保留剂量学比较。

背景/目的：一种新的线基放射外科（SRS）系统，HyperArc，应用于非共面体积调制电弧治疗（VMAT）技术，被开发并在临床实践中发布。该研究的目的是评估两种SRS系统（GammaKnife和HyperArc）在单靶点和三靶点病例中脑保留的剂量学性能。患者和方法：回顾性分析83例使用GammaKnife SRS治疗的患者（单转移35例，双转移24例，三重转移24例）。使用HyperArc重新计算治疗方案。比较两种系统的剂量学参数，包括符合性指数（CI）、梯度指数（GI）和接受2-20 Gy的脑容量（V2-V20）。结果：GammaKnife与HyperArc在计划靶体积（PTV）的D99上无显著差异。HyperArc表现出优越的CI100，接近1.0。全脑V4-V20减去PTV， HyperArc明显低于GammaKnife。在单靶点病例中，HyperArc的GI显著降低，而在三靶点病例中，GI则更高。HyperArc的V12卷与GammaKnife的V12卷相当，即使在卷3的情况下也是如此。结论：在单至三重转移的脑保留方面，HyperArc显示出与GammaKnife相当或更好的剂量学性能。这些发现支持HyperArc作为SRS计划的有效替代方案。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Anticancer research 医学-肿瘤学

CiteScore

3.70

自引率

10.00%

发文量

566

审稿时长

2 months

期刊介绍： ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed. ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies). Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.